LoginRegister

    Lupin launches generic Kapvay tablets in US

    Written by Ruby Khatun Khatun   |  
    Lupin launches generic Kapvay tablets in US

    Mumbai: Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets for the treatment of attention deficit hyperactivity disorder (ADHD).


    The Clonidine Hydrochloride extended-release tablets 0.1mg have received an approval from the United States Food and Drug Administration (FDA) earlier.


    Lupin's Clonidine Hydrochloride ER tablets are the generic equivalent of Concordia International Corp's Kapvay® tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.


    Kapvay tablets had annual sales of approximately USD 66 million in the US.

    ADHDattention deficit hyperactivity disorderClonidine HydrochlorideClonidine Hydrochloride extended-release tabletsConcordia International CorpFDAgenericgeneric equivalentKapvay tabletsLaunchlaunchesLupinUnited States Food and Drug AdministrationUS
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X